Eli Lilly and Company Reports Positive Phase IIIb Data for Taltz and Zepbound Combination

Eli Lilly and Company has announced positive topline results from the TOGETHER-PsO Phase IIIb trial evaluating Taltz (ixekizumab) in combination with Zepbound (tirzepatide) in adults with moderate to severe plaque psoriasis and obesity or overweight, each with at least one additional weight-related comorbidity.

The 52-week, multicentre, randomised study enrolled 274 participants assigned to Taltz alone or in combination with Zepbound. All received lifestyle counselling. The primary endpoint was achieving PASI 100 (complete skin clearance) and at least 10% weight loss at week 36.

Results showed 27.1% of combination-treated patients met the dual endpoint versus 5.8% with Taltz alone. PASI 100 was achieved by 40.6% in the combination arm compared to 29% with monotherapy.

Adverse events were mostly mild to moderate. Lilly also reported recent positive Phase III data for Retevmo in early-stage RET fusion-positive NSCLC.

27-02-2026